165 related articles for article (PubMed ID: 35711379)
1. Cardiotoxicity Related to Immune Checkpoint Inhibitors: A Real-World Retrospective Analysis.
She J; Liu H; Wu H; Tuerhongjiang G; Zheng T; Bai L
Front Cardiovasc Med; 2022; 9():838488. PubMed ID: 35711379
[TBL] [Abstract][Full Text] [Related]
2. Immune Checkpoint Inhibitor-Associated Cardiotoxicity in Solid Tumors: Real-World Incidence, Risk Factors, and Prognostic Analysis.
Chen X; Jiang A; Zhang R; Fu X; Liu N; Shi C; Wang J; Zheng X; Tian T; Liang X; Ruan Z; Yao Y
Front Cardiovasc Med; 2022; 9():882167. PubMed ID: 35669482
[TBL] [Abstract][Full Text] [Related]
3. Clinical characteristics and management of immune checkpoint inhibitor-related cardiotoxicity: A single-center experience.
Xiao J; Li X; Wang X; Guan Y; Liu H; Liang J; Li Y; Wang B; Wang J
Front Cardiovasc Med; 2023; 10():1093383. PubMed ID: 37089888
[TBL] [Abstract][Full Text] [Related]
4. Cardiotoxicity associated with immune checkpoint inhibitors: Current status and future challenges.
Gan L; Liu D; Ma Y; Chen X; Dai A; Zhao S; Jin X; Gu G
Front Pharmacol; 2022; 13():962596. PubMed ID: 36110551
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular adverse events induced by immune checkpoint inhibitors: A real world study from 2018 to 2022.
Wu S; Bai H; Zhang L; He J; Luo X; Wang S; Fan G; Sun N
Front Cardiovasc Med; 2022; 9():969942. PubMed ID: 36035942
[TBL] [Abstract][Full Text] [Related]
6. Cardiotoxicity in cancer immune-checkpoint therapy: Mechanisms, clinical evidence, and management strategies.
Sun JY; Qu Q; Lou YX; Hua Y; Sun GZ; Sun W; Kong XQ
Int J Cardiol; 2021 Dec; 344():170-178. PubMed ID: 34563597
[TBL] [Abstract][Full Text] [Related]
7. Real-World Clinical and Economic Outcomes in Selected Immune-Related Adverse Events Among Patients with Cancer Receiving Immune Checkpoint Inhibitors.
Zheng Y; Kim R; Yu T; Gayle JA; Wassel CL; Dreyfus J; Phatak H; George S
Oncologist; 2021 Nov; 26(11):e2002-e2012. PubMed ID: 34327774
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Inhibitor (ICI)-Related Cardiotoxicity.
Zarifa A; Lopez-Mattei J; Palaskas NL; Iliescu C; Durand JB; Kim PY
Adv Exp Med Biol; 2021; 1342():377-387. PubMed ID: 34972975
[TBL] [Abstract][Full Text] [Related]
9. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
10. Immune checkpoint inhibitor-related adverse cardiac events in patients with lung cancer: a systematic review and meta-analysis.
Zhang XT; Ge N; Xiang ZJ; Liu T
Cancer Cell Int; 2022 Nov; 22(1):363. PubMed ID: 36402980
[TBL] [Abstract][Full Text] [Related]
11. Association of Programmed Cell Death Ligand 1 Expression Status With Receipt of Immune Checkpoint Inhibitors in Patients With Advanced Non-Small Cell Lung Cancer.
Leapman MS; Presley CJ; Zhu W; Soulos PR; Adelson KB; Miksad RA; Boffa DJ; Gross CP
JAMA Netw Open; 2020 Jun; 3(6):e207205. PubMed ID: 32511721
[TBL] [Abstract][Full Text] [Related]
12. Clinical manifestation and management of immune checkpoint inhibitor-associated cardiotoxicity.
Guo X; Wang H; Zhou J; Li Y; Duan L; Si X; Zhang L; Fang L; Zhang L
Thorac Cancer; 2020 Feb; 11(2):475-480. PubMed ID: 31849171
[TBL] [Abstract][Full Text] [Related]
13. How can we manage the cardiac toxicity of immune checkpoint inhibitors?
Poto R; Marone G; Pirozzi F; Galdiero MR; Cuomo A; Formisano L; Bianco R; Della Corte CM; Morgillo F; Napolitano S; Troiani T; Tocchetti CG; Mercurio V; Varricchi G
Expert Opin Drug Saf; 2021 Jun; 20(6):685-694. PubMed ID: 33749484
[No Abstract] [Full Text] [Related]
14. Real-world data analysis of immune checkpoint inhibitors in stage III-IV adenocarcinoma and squamous cell carcinoma.
Sun M; Ji H; Xu N; Jiang P; Qu T; Li Y
BMC Cancer; 2022 Jul; 22(1):762. PubMed ID: 35831785
[TBL] [Abstract][Full Text] [Related]
15. Incidence, predictors and 6-month overall outcome of acute kidney injury in Chinese patients receiving PD-1 inhibitors.
Qin Z; Liu K; Xu X; Li T; Ge Y; Wu B; Xing C; Mao H
Future Oncol; 2022 May; 18(16):1951-1962. PubMed ID: 35232231
[TBL] [Abstract][Full Text] [Related]
16. A Systematic Review of the Mechanisms Involved in Immune Checkpoint Inhibitors Cardiotoxicity and Challenges to Improve Clinical Safety.
Rubio-Infante N; Ramírez-Flores YA; Castillo EC; Lozano O; García-Rivas G; Torre-Amione G
Front Cell Dev Biol; 2022; 10():851032. PubMed ID: 35433707
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy as second-line treatment and beyond for non-small cell lung cancer in a single center of China: Outcomes, toxicities, and clinical predictive factors from a real-world retrospective analysis.
Chen M; Li Q; Xu Y; Zhao J; Zhang L; Wei L; Zhong W; Wang M
Thorac Cancer; 2020 Jul; 11(7):1955-1962. PubMed ID: 32468726
[TBL] [Abstract][Full Text] [Related]
18. Extensive CArdioVAscular Characterization and Follow-Up of Patients Receiving Immune Checkpoint Inhibitors: A Prospective Multicenter Study.
Delombaerde D; De Sutter J; Croes L; Vervloet D; Moerman V; Van de Veire N; Willems AM; Wouters K; Peeters M; Prenen H; Vulsteke C
Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111382
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular adverse events are associated with usage of immune checkpoint inhibitors in real-world clinical data across the United States.
Jain P; Gutierrez Bugarin J; Guha A; Jain C; Patil N; Shen T; Stanevich I; Nikore V; Margolin K; Ernstoff M; Velcheti V; Barnholtz-Sloan J; Dowlati A
ESMO Open; 2021 Oct; 6(5):100252. PubMed ID: 34461483
[TBL] [Abstract][Full Text] [Related]
20. [Cardiotoxicity of Anti-PD-L1 Antibody and the Effect of Levothyroxine
in Attenuating the Related Mortality in Mice].
Chen Z; Wang M; Gao S; Guo H; Wang G; Zhou G
Zhongguo Fei Ai Za Zhi; 2021 Jun; 24(6):394-403. PubMed ID: 34157799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]